{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+Test+Product&page=2",
    "query": {
      "intervention": "Vehicle of Test Product",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vehicle+of+Test+Product&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T09:35:25.483Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04883736",
      "title": "A Study Comparing Tretinoin Gel Microsphere, 0.1% and RETIN-A MICRO ® Gel Microsphere, 0.1% in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tretinoin Gel Microsphere, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "RETIN-A MICRO® (Tretinoin) Gel Microsphere, 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 973,
      "start_date": "2020-08-31",
      "completion_date": "2021-04-16",
      "has_results": false,
      "last_update_posted_date": "2021-05-12",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04883736"
    },
    {
      "nct_id": "NCT03433378",
      "title": "To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tretinoin cream, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "RETIN-A® (tretinoin) cream, 0.05%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle of the test product",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sun Pharmaceutical Industries, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 700,
      "start_date": "2017-08-04",
      "completion_date": "2018-01-26",
      "has_results": false,
      "last_update_posted_date": "2018-05-18",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03433378"
    },
    {
      "nct_id": "NCT02005666",
      "title": "To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel",
          "type": "DRUG"
        },
        {
          "name": "DUAC® Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zydus Lifesciences Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 850,
      "start_date": "2013-11",
      "completion_date": "2016-09-28",
      "has_results": true,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 12,
      "location_summary": "Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more",
      "locations": [
        {
          "city": "Dinuba",
          "state": "California"
        },
        {
          "city": "Santa Ana",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02005666"
    },
    {
      "nct_id": "NCT02840461",
      "title": "Clinical Endpoint Study of Ivermectin 1% Cream",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Moderate to Severe Papulopustular Rosacea"
      ],
      "interventions": [
        {
          "name": "Ivermectin Cream, 1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo/Vehicle cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 630,
      "start_date": "2016-06",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2020-06-02",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 1,
      "location_summary": "Arlington Heights, Illinois",
      "locations": [
        {
          "city": "Arlington Heights",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02840461"
    },
    {
      "nct_id": "NCT05260359",
      "title": "Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sunburn"
      ],
      "interventions": [
        {
          "name": "6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation",
          "type": "DRUG"
        },
        {
          "name": "6% Bemotrizinol (BEMT) dispersion in petrolatum",
          "type": "DRUG"
        },
        {
          "name": "Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT",
          "type": "OTHER"
        },
        {
          "name": "Petrolatum vehicle",
          "type": "OTHER"
        },
        {
          "name": "0.9% Saline",
          "type": "OTHER"
        },
        {
          "name": "Sodium Lauryl Sulfate 0.1% (SLS)",
          "type": "OTHER"
        },
        {
          "name": "Undosed patch",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "dsm-firmenich Switzerland AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 224,
      "start_date": "2022-02-23",
      "completion_date": "2022-04-08",
      "has_results": false,
      "last_update_posted_date": "2022-08-26",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 1,
      "location_summary": "Piscataway, New Jersey",
      "locations": [
        {
          "city": "Piscataway",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05260359"
    },
    {
      "nct_id": "NCT02886715",
      "title": "A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Tazarotene Cream 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Tazorac®",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fougera Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1110,
      "start_date": "2016-09-21",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-08-17",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Conway",
          "state": "Arkansas"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02886715"
    },
    {
      "nct_id": "NCT05521438",
      "title": "Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Netherton Syndrome"
      ],
      "interventions": [
        {
          "name": "QRX003-2% Lotion",
          "type": "DRUG"
        },
        {
          "name": "QRX003-4% Lotion QAM",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        },
        {
          "name": "QRX003-4% Lotion BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quoin Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2022-06-23",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-16",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 5,
      "location_summary": "San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Quincy",
          "state": "Massachusetts"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05521438"
    },
    {
      "nct_id": "NCT03682601",
      "title": "Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sexual Pain Disorders",
        "Postmenopausal Symptoms",
        "Vulvovaginal Atrophy",
        "Female Sexual Dysfunction",
        "Dyspareunia",
        "Vulvodynia",
        "Vestibulodynia",
        "Arousal Disorders, Sexual",
        "Genito-Pelvic Pain/Penetration Disorder",
        "Female Sexual Arousal Disorder"
      ],
      "interventions": [
        {
          "name": "5% sinecatechins ointment",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "10% sinecatechins ointment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GTO Pharmaceutical, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "20 Years to 70 Years · Female only"
      },
      "enrollment_count": 32,
      "start_date": "2018-08-30",
      "completion_date": "2021-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-07-27",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 4,
      "location_summary": "New York, New York • Nyack, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nyack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03682601"
    },
    {
      "nct_id": "NCT02952898",
      "title": "Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Actinic Keratosis"
      ],
      "interventions": [
        {
          "name": "GDC 695",
          "type": "DRUG"
        },
        {
          "name": "Diclofenac Sodium Gel, 3%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Balmoral Medical company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 665,
      "start_date": "2016-10-27",
      "completion_date": "2017-09-06",
      "has_results": true,
      "last_update_posted_date": "2020-01-07",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 16,
      "location_summary": "Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more",
      "locations": [
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Ramon",
          "state": "California"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "North Miami Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02952898"
    },
    {
      "nct_id": "NCT03954444",
      "title": "A Clinical Endpoint Bioequivalence Study of \"Oxymetazoline Hydrochloride Cream\"",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "Oxymetazoline Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Rhofade Cream, 1%",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1105,
      "start_date": "2019-04-15",
      "completion_date": "2020-02-27",
      "has_results": true,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-09-28T09:35:25.483Z",
      "location_count": 1,
      "location_summary": "Lynchburg, Virginia",
      "locations": [
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954444"
    }
  ]
}